BioCentury
ARTICLE | Clinical News

Lilly's ixekizumab meets in plaque psoriasis trials

August 22, 2014 12:28 AM UTC

Eli Lilly and Co. (NYSE:LLY) said subcutaneous ixekizumab ( LY2439821) met the co-primary endpoints vs. placebo or etanercept in each of the Phase III UNCOVER-1, -2 and -3 trials to treat moderate to severe plaque psoriasis. Lilly said 78-90% of patients who received ixekizumab achieved a 75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) response at week 12. The compound also improved static Physician Global Assessment (sPGA) scores; however, details were not disclosed. Additionally, Lilly said 31-41% of patients who received ixekizumab achieved a PASI 100 response at week 12. The double-blind, international trials enrolled a total of 3,866 patients.

Next half, Lilly plans to submit worldwide regulatory applications for ixekizumab to treat moderate to severe plaque psoriasis. The humanized mAb against IL-17A is also in Phase III testing to treat psoriatic arthritis. ...